Nothing Special   »   [go: up one dir, main page]

MX344885B - Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido. - Google Patents

Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.

Info

Publication number
MX344885B
MX344885B MX2008014321A MX2008014321A MX344885B MX 344885 B MX344885 B MX 344885B MX 2008014321 A MX2008014321 A MX 2008014321A MX 2008014321 A MX2008014321 A MX 2008014321A MX 344885 B MX344885 B MX 344885B
Authority
MX
Mexico
Prior art keywords
composition
rosuvastatin calcium
obtaining
product obtained
lipids
Prior art date
Application number
MX2008014321A
Other languages
English (en)
Other versions
MX2008014321A (es
Inventor
Estrada Flores Luis
Lizeth Maya Ayala Kenia
Original Assignee
Psicofarma S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psicofarma S A De C V filed Critical Psicofarma S A De C V
Priority to MX2008014321A priority Critical patent/MX344885B/es
Priority to NZ593349A priority patent/NZ593349A/xx
Priority to PCT/MX2009/000081 priority patent/WO2010053343A1/es
Priority to US13/128,329 priority patent/US20120269890A1/en
Priority to BRPI0921019A priority patent/BRPI0921019A2/pt
Priority to JP2011535525A priority patent/JP2012508230A/ja
Priority to CA2744820A priority patent/CA2744820C/en
Priority to EP09825024A priority patent/EP2347758A4/en
Publication of MX2008014321A publication Critical patent/MX2008014321A/es
Publication of MX344885B publication Critical patent/MX344885B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención describe una composición de resuvastatina cálcica y su proceso de obtención, en la cual por su procedimiento de obtención y la selección de los componentes de la composición no se requiere de sales de fosfato tribásico para ser estable y que también tiene una adecuada biodisponibilidad, es útil para lograr una disminución de los niveles de lípidos y/o colesterol en el cuerpo, así como el método de fabricación de esta composición.
MX2008014321A 2008-11-10 2008-11-10 Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido. MX344885B (es)

Priority Applications (8)

Application Number Priority Date Filing Date Title
MX2008014321A MX344885B (es) 2008-11-10 2008-11-10 Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
NZ593349A NZ593349A (en) 2008-11-10 2009-07-29 Process for obtaining a composition of rosuvastatin calcium and product obtained
PCT/MX2009/000081 WO2010053343A1 (es) 2008-11-10 2009-07-29 Proceso para la obtención de una composición de rosuvastatina cálcica y producto obtenido
US13/128,329 US20120269890A1 (en) 2008-11-10 2009-07-29 Process for obtaining a rosuvastatin calcium composition and obtained product
BRPI0921019A BRPI0921019A2 (pt) 2008-11-10 2009-07-29 processo para obtenção de uma composição de rosuvastatina cálcica e produto obtido
JP2011535525A JP2012508230A (ja) 2008-11-10 2009-07-29 ロスバスタチンカルシウム組成物の取得方法及び得られた産物
CA2744820A CA2744820C (en) 2008-11-10 2009-07-29 Process for obtaining a rosuvastatin calcium composition and obtained product
EP09825024A EP2347758A4 (en) 2008-11-10 2009-07-29 METHOD FOR OBTAINING A COMPOSITION OF ROSUVASTATIN AND CALCIUM AND THE PRODUCT OBTAINED

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2008014321A MX344885B (es) 2008-11-10 2008-11-10 Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.

Publications (2)

Publication Number Publication Date
MX2008014321A MX2008014321A (es) 2010-06-07
MX344885B true MX344885B (es) 2017-01-10

Family

ID=42153048

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008014321A MX344885B (es) 2008-11-10 2008-11-10 Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.

Country Status (8)

Country Link
US (1) US20120269890A1 (es)
EP (1) EP2347758A4 (es)
JP (1) JP2012508230A (es)
BR (1) BRPI0921019A2 (es)
CA (1) CA2744820C (es)
MX (1) MX344885B (es)
NZ (1) NZ593349A (es)
WO (1) WO2010053343A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2602911C2 (ru) 2011-05-20 2016-11-20 Астразенека Юкей Лимитед Фармацевтическая композиция, содержащая кальциевую соль розувастатина
WO2013024425A1 (en) * 2011-08-15 2013-02-21 Technion Research And Development Foundation Ltd. Combinations of corroles and statins
JP6161867B2 (ja) * 2011-11-17 2017-07-12 株式会社アドバンテスト 滑沢剤の展延解析装置、方法、プログラム、記録媒体
EP2787987B1 (de) 2011-12-08 2016-06-01 Hexal AG Neue pharmazeutische statin-zusammensetzung
JP2016098187A (ja) * 2014-11-19 2016-05-30 ニプロ株式会社 口腔内崩壊錠
JP6108635B2 (ja) * 2015-05-14 2017-04-05 ダイト株式会社 ロスバスタチン含有口腔内速崩壊錠
JP6167192B2 (ja) * 2016-01-19 2017-07-19 株式会社アドバンテスト 滑沢剤の展延解析装置、方法、プログラム、記録媒体
CN110151725B (zh) * 2019-06-26 2021-06-18 海南通用三洋药业有限公司 一种稳定的瑞舒伐他汀钙胶囊剂及其制备方法
CN110974793A (zh) * 2019-12-26 2020-04-10 鲁南制药集团股份有限公司 一种瑞舒伐他汀钙片剂及其制备方法
CN113230223B (zh) * 2021-05-13 2023-04-07 宜昌人福药业有限责任公司 阿托伐他汀钙薄膜包衣片的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8679534B2 (en) * 1997-12-12 2014-03-25 Andrx Labs, Llc HMG-CoA reductase inhibitor extended release formulation
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
AR030414A1 (es) * 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
GB0111077D0 (en) * 2001-05-04 2001-06-27 Biochemie Gmbh Organic compounds
DE10204336A1 (de) * 2002-02-01 2003-08-14 Merck Patent Gmbh Verwendung von Mehrschichtpigmenten im Lebensmittel- und Pharmabereich
US20030171407A1 (en) * 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
CA2483099A1 (en) * 2002-05-03 2003-11-13 Hexal Ag Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor
GB0217306D0 (en) * 2002-07-25 2002-09-04 Novartis Ag Compositions comprising organic compounds
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
CA2513532C (en) * 2003-02-20 2012-01-24 Bpsi Holdings, Inc. Pearlescent film coating systems and substrates coated therewith
CA2573857A1 (en) * 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
WO2006134604A1 (en) * 2005-06-15 2006-12-21 Hetero Drugs Limited Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor
EP1741427A1 (en) * 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
US20070053892A1 (en) * 2005-09-07 2007-03-08 Everett Laboratories, Inc. Methods and kits for co-administration of nutritional supplements
US20070238716A1 (en) * 2006-03-14 2007-10-11 Murthy Ayanampudi S R Statin stabilizing dosage formulations
WO2008062476A2 (en) * 2006-10-31 2008-05-29 Glenmark Pharmaceutical Limited Pharmaceutical composition comprising rosuvastatin or pharmaceutically accepatble salts thereof
EP2120928A2 (en) * 2007-02-15 2009-11-25 Pfizer Limited Pharmaceutical compositions and methods for ccr5 antagonists
US8404283B2 (en) * 2007-10-26 2013-03-26 Eurofarma Laboratorios LTDA Standardized plant extract, process for obtaining the same and uses thereof

Also Published As

Publication number Publication date
JP2012508230A (ja) 2012-04-05
BRPI0921019A2 (pt) 2015-12-22
MX2008014321A (es) 2010-06-07
NZ593349A (en) 2012-12-21
WO2010053343A1 (es) 2010-05-14
CA2744820A1 (en) 2010-05-14
EP2347758A4 (en) 2012-04-25
EP2347758A1 (en) 2011-07-27
CA2744820C (en) 2016-03-01
US20120269890A1 (en) 2012-10-25

Similar Documents

Publication Publication Date Title
MX344885B (es) Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
WO2010033587A3 (en) Methods for treating progressive multiple sclerosis
HK1148791A1 (en) Steel, process for the manufacture of a steel blank and process for the manufacture of a component of the steel
MY162809A (en) Calcium sulphate-based products and methods for the manufacture thereof
MX2011001679A (es) Derivados de flavina.
EP2308954A4 (en) PROCESS FOR THE PRODUCTION OF A HIGH-PURITY PHOSPHOLIPID AND A HIGH-PURITY, GLYCEROSPHOLIPID SPHINGOMYELIC OF THE PLASMALOGEN TYPE OBTAINED BY USING THE SAME
PT2143688T (pt) Processo de fabrico de suspensões aquosas de carbonato de cálcio e suspensões obtidas assim como as suas utilizações
PL2297169T3 (pl) Sposób wytwarzania kwasu aminoalkilenofosfonowego
ATE475437T1 (de) Antimikrobielles medizintechnisches produkt, verfahren zu seiner herstellung und verwendung
UA86731C2 (ru) Делимая галеновая форма модифицированного высвобождения активного ингредиента
WO2008053334A3 (en) An improved process for preparing rosuvastatin calcium
SI2373745T1 (sl) Vodne gošče polnil iz finih delcev, postopek za njihovo pripravo in njihova uporaba za izdelavo papirjev, ki vsebuejo polnila
WO2011028423A3 (en) Method for producing a stable oxidizing biocide
ZA201100842B (en) Grinding method for the manipulation or preservation of calcium phosphate hybrid properties
EP2865791A4 (en) PROCESS FOR PRODUCING POROUS CALCIUM PHOSPHATE BODY AND POROUS CALCIUM PHOSPHATE BODY PRODUCED THEREBY
MX340592B (es) Proceso para la produccion de dioxido de cloro.
WO2012057454A3 (ko) 골 이식재 제조방법 및 그로 인해 제조된 골 이식재
WO2007084858A3 (en) Biomimetic hydroxyapatite synthesis
IN2015KN00212A (es)
MX2009009490A (es) Profarmacos novedosos.
AP2012006173A0 (en) Process and reagents for the inhibition or reduction of scale formation during phosphoric acid production.
ATE516290T1 (de) Verfahren zur herstellung von buprenorphin und derivaten von buprenorphin
WO2010035284A3 (en) An improved process for the preparation of rosuvastatin calcium
MY158882A (en) Dimethyl disulphide derived at least partially from renewable materials
WO2011147034A8 (en) Prostaglandin-bisphosphonate conjugate compounds, methods of making same, and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration